Professor Sir Andrew Pollard, director of the Oxford Vaccine Group, has said that the UK is "going to have to live with" COVID-19, BBC News reported on Wednesday.
Prof Pollard, speaking to the Commons Science and Technology Committee, was quoted as saying that "variants and their emergence" will "continue to happen".
He added: "But in the end, we're going to have to come back to focusing on the really important public health issue, which is the hospitalisation and the death. If transmission is disconnected by vaccine immunity from the severe disease, to a large extent, then we'll need to monitor new variants, perhaps, if we need to find new vaccines and so on - but we are going to have to live with it being in our communities and transmitting."
Merck launches Phase 3 trial for dengue vaccine candidate V181
BioNet and Bio Farma sign MoU on TdaP vaccine
Dx&Vx accelerates universal COVID-19 vaccine development
Moderna withdraws application for flu-COVID combination vaccine pending additional efficacy data
CTP delivers 18,000 sqm Serbian facility for SCHOTT Pharma to support global expansion
LakeShore Biopharma launches novel packaging solution for YSJA rabies vaccine (Vero cell)
Scancell partners with NHS Cancer Vaccine Launch Pad to accelerate melanoma trial recruitment
Orexo reports positive results for powder-based intranasal vaccine using AmorphOX technology
GC Biopharma's BARYTHRAX receives Korean regulatory approval
GSK grants USD2m to boost adult vaccination efforts
Valneva and LimmaTech begin Phase 2 infant trial for Shigella vaccine candidate S4V2
Circio Holding and Entos Pharmaceuticals collaborate on circular RNA delivery
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100